Drug Trial Radar · NCT07110883
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 15, 2024
Primary completion
Oct 31, 2026
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
SYS6023Drug
SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cyecle 1 (each cycle is 21 days).
- Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) (according to NCI-CTCAE 5.0)Time frame: Baseline up to 28 days post last dose,. Up to approximately 2 years.
- Recommended Phase 2 Dose(RP2D)Time frame: Up to approximately 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Tumor Hospital of Harbin
Harbin, Heilongjiang, China · Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.